Page last updated: 2024-08-05 13:10:23
triazolopyridazine
null
ChEBI ID: 48384
Members (6)
Member | Definition | Role |
---|---|---|
3-[(4-fluorophenyl)methylthio]-6-pyridin-4-yl-[1,2,4]triazolo[4,3-b]pyridazine | 3-[(4-fluorophenyl)methylthio]-6-pyridin-4-yl-[1,2,4]triazolo[4,3-b]pyridazine | |
3-methyl-6-(1-pyrrolidinyl)-[1,2,4]triazolo[4,3-b]pyridazine | 3-methyl-6-(1-pyrrolidinyl)-[1,2,4]triazolo[4,3-b]pyridazine | |
3-methyl-6-prop-2-enoxy-[1,2,4]triazolo[4,3-b]pyridazine | 3-methyl-6-prop-2-enoxy-[1,2,4]triazolo[4,3-b]pyridazine | |
6-(2-furanyl)-3-(2-pyridinylmethylthio)-[1,2,4]triazolo[4,3-b]pyridazine | 6-(2-furanyl)-3-(2-pyridinylmethylthio)-[1,2,4]triazolo[4,3-b]pyridazine | |
AMG-208 | A member of the class of quinolines that is 7-methoxyquinoline substituted at position 4 by a (6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy group. AMG exhibits antitumour activity, particularly in prostate cancer. | AMG-208 |
sgx 523 | A member of the class of triazolopyridazines that is 6-(1-methylpyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazine-3-thiol in which the thiol hydrogen is replaced by a quinolin-6-yl group. | SGX-523 |
Research
Studies (33)
Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (12.12) | 29.6817 |
2010's | 21 (63.64) | 24.3611 |
2020's | 8 (24.24) | 2.80 |
Study Types
Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
---|---|---|
Trials | 1 (1.67%) | 5.53% |
Reviews | 2 (3.33%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 57 (95.00%) | 84.16% |